Large gap with delayed quotes
|
Last quote
07/17/2026
-
17:31:48
|
Bid
07/17/2026 -
17:40:00
|
Bid Volume |
Ask
07/17/2026 -
17:40:00
|
Ask Volume |
|---|---|---|---|---|
|
51.80
0.00
(
0.00% )
|
51.20
|
200 |
52.00
|
200 |
Analysis date: 14.07.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 06.02.2026.
Interest
Strong
Strong
Three stars since 03.07.2026.
Earnings Rev Trend
0.10
0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is positive since 03.07.2026 at a price of 54.30.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 30.06.2026.
4wk Rel Perf
2.91%
2.91%
The four-week dividend-adjusted overperformance versus STOXX600 is 2.91%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 13.01.2026.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.10%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.21%.
Mkt Cap in $bn
0.80
0.80
With a market capitalization <$2bn, BASILEA PHARMACEUTIC is considered a small-cap stock.
G/PE Ratio
-0.27
-0.27
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
63.88
63.88
The estimated PE is for the year 2028.
LT Growth
-17.47%
-17.47%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
3
3
Over the last seven weeks, an average of 3 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
63
63
For 1% of index variation, the stock varies on average by 0.63%.
Correlation
0.28
0.28
Stock movements are strongly independent of index variations.
Value at Risk
7.22
7.22
The value at risk is estimated at CHF 7.22. The risk is therefore 13.89%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
12.11.2004
12.11.2004